FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
Research reveals how ectopic NMDA receptor expression in triple-negative breast cancer triggers autoimmune disease through antibody maturation. The study shows NMDAR expression recruits B cells and drives affinity maturation, producing antibodies that can cross the blood-brain barrier and cause neurological symptoms while constraining tumor growth.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
New antibody-based approaches demonstrate clinical benefits across multiple cancer types, including improved survival in triple-negative breast cancer, enhanced tumor detection via PET imaging, and activity in relapsed mantle cell lymphoma.
The ASCENT-04 trial showed sacituzumab govitecan plus pembrolizumab improved progression-free survival in PD-L1-positive TNBC without increased toxicity. Meanwhile, experts debate whether ADCs function as targeted therapy or advanced chemotherapy, with sequencing questions remaining unresolved.
A University of Houston researcher has joined a $3.2 million effort to develop a new drug targeting MDM2, a cancer-driving protein in triple-negative breast cancer. The compound has shown ability to shrink tumors in early laboratory models.
New research highlights circulating tumor DNA as a prognostic tool in early-stage triple-negative breast cancer, while leronlimab demonstrates long-term survival signals in heavily pretreated metastatic patients through CCR5 receptor blockade.
A first-in-human trial shows individualized neoantigen mRNA vaccines generated multi-year T cell responses in early-stage TNBC patients, with 82.9% of targeted mutations eliciting measurable immune activation not detectable before vaccination.
Two clinical trials demonstrate efficacy of talimogene laherparepvec (T-VEC) oncolytic virus therapy in HER2-negative breast cancer and nonmelanoma skin cancers, with favorable safety profiles and durable responses in subset of patients.
Researchers at The University of Texas MD Anderson Cancer Center developed a computational approach using tumor-specific total mRNA expression (TmS) that outperformed current methods for predicting chemotherapy response in triple-negative breast cancer patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07552181 |
Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product, MO-03, in Patients With Early Stage Triple Negative Breast Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07536815 |
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC) |
AVAILABLE | |
| NCT07491822 |
A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer |
NOT_YET_RECRUITING | NA |
| NCT07441512 |
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation |
NOT_YET_RECRUITING | PHASE2 |
| NCT07376629 |
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC |
ENROLLING_BY_INVITATION | PHASE2 |
| NCT07021261 |
Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients |
NOT_YET_RECRUITING | PHASE3 |
| NCT07017673 |
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer |
RECRUITING | PHASE2 |
| NCT06991790 |
Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration |
RECRUITING | |
| NCT06769425 |
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT06746870 |
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer |
NOT_YET_RECRUITING | PHASE2 |
